Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Harvard Medical School, Boston, MA, United States; Department of Psychiatry, Brigham and Women's Faulkner Hospital, Boston, MA, United States.
Addict Behav. 2021 Sep;120:106988. doi: 10.1016/j.addbeh.2021.106988. Epub 2021 May 15.
Tobacco use and resultant health complications disproportionately impact individuals with psychiatric disorders. Inpatient psychiatric hospitalizations provide an opportunity to initiate tobacco treatment. In this study, electronic medical record review identified demographic and clinical information, smoking status, and tobacco cessation treatment offered for adults hospitalized on two acute, non-smoking psychiatric units in Massachusetts from January 2016 to March 2018. We additionally conducted semi-structured interviews with 15 inpatient nursing, psychiatry, psychology and social work providers regarding their tobacco cessation treatment practices and perceived facilitators and barriers to addressing tobacco use on psychiatric inpatient units. Chart review identified 1099 of 3140 (35%) people admitted reporting daily tobacco smoking. On discharge, 5 (0.005%) of inpatient smokers received a prescription for varenicline, 43 (0.04%) for dual-nicotine replacement therapy, 211 (19.2%) for nicotine patch, and 5 (0.005%) for bupropion. Barriers to inpatient smoking cessation treatment initiation identified in qualitative interviews included: 1) smoking cessation as low priority, 2) smoking cessation as the responsibility of outpatient providers, 3) lack of education about tobacco treatment, and 4) treatment discussions framed as preventing withdrawal. Given the potential to impact a large percentage of psychiatric tobacco users, future interventions should investigate provision of tobacco cessation counseling and pharmacotherapy in inpatient settings, with interventions that take into account the barriers and opportunities presented in this study.
烟草使用及其导致的健康并发症不成比例地影响患有精神障碍的个体。住院精神病院为开始进行烟草治疗提供了机会。在这项研究中,电子病历回顾确定了人口统计学和临床信息、吸烟状况以及 2016 年 1 月至 2018 年 3 月马萨诸塞州两家急性非吸烟精神病院住院的成年人提供的烟草戒断治疗。我们还对 15 名住院护理、精神病学、心理学和社会工作提供者进行了半结构化访谈,了解他们的烟草戒断治疗实践以及在精神病住院病房解决烟草使用问题的促进因素和障碍。病历回顾确定了 3140 名(35%)入院患者中有 1099 名报告每日吸烟。出院时,5 名(0.005%)住院吸烟者接受了伐尼克兰处方,43 名(0.04%)接受了双重尼古丁替代疗法,211 名(19.2%)接受了尼古丁贴片,5 名(0.005%)接受了安非他酮。定性访谈中确定的住院戒烟治疗启动障碍包括:1)戒烟优先级低,2)戒烟是门诊提供者的责任,3)缺乏关于烟草治疗的教育,4)将治疗讨论框定为预防戒断。鉴于有潜力影响很大一部分精神病烟草使用者,未来的干预措施应调查在住院环境中提供烟草戒断咨询和药物治疗的情况,并考虑到本研究中提出的障碍和机会。